See more : Cardio Diagnostics Holdings, Inc. (CDIO) Income Statement Analysis – Financial Results
Complete financial analysis of Q BioMed Inc. (QBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Q BioMed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CTEEP – Companhia de Transmissão de Energia Elétrica Paulista S.A. (TRPL4.SA) Income Statement Analysis – Financial Results
- SIS Limited (SIS.BO) Income Statement Analysis – Financial Results
- Sandfire Resources America Inc. (SRAFF) Income Statement Analysis – Financial Results
- M LAKHAMSI INDUSTRIES LIMITED (MLINDLTD.BO) Income Statement Analysis – Financial Results
- Engie Energia Chile S.A. (ECL.SN) Income Statement Analysis – Financial Results
Q BioMed Inc. (QBIO)
About Q BioMed Inc.
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.35K | 195.60K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 293.34K | 246.85K | 326.01K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 | 38.05K | 0.00 |
| Gross Profit | -8.99K | -51.25K | -296.01K | -50.00K | 0.00 | 0.00 | 0.00 | 0.00 | -38.05K | 0.00 |
| Gross Profit Ratio | -3.16% | -26.20% | -986.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 125.38K | 1.07M | 1.88M | 3.54M | 3.24M | 3.10M | 1.31M | 598.00K | 0.00 | 0.00 |
| General & Administrative | 3.28M | 6.26M | 10.97M | 4.48M | 5.78M | 9.27M | 5.03M | 354.14K | 38.05K | 500.00 |
| Selling & Marketing | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.31M | 6.26M | 10.97M | 4.48M | 5.78M | 9.27M | 5.03M | 354.14K | 38.05K | 500.00 |
| Other Expenses | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.44M | 7.34M | 12.85M | 8.02M | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 500.00 |
| Cost & Expenses | 3.73M | 7.58M | 13.18M | 8.02M | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 500.00 |
| Interest Income | 0.00 | 506.92K | 296.22K | 1.46M | 0.00 | 138.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38M | 506.92K | 296.22K | 1.46M | 162.10K | 760.31K | 480.29K | 14.51K | 0.00 | 0.00 |
| Depreciation & Amortization | 50.00K | 50.00K | 50.00K | 50.00K | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 0.00 |
| EBITDA | -617.63K | -7.68M | -13.15M | -7.97M | -89.00K | -1.41M | -344.72K | -119.97K | 0.00 | -500.00 |
| EBITDA Ratio | -217.21% | -3,751.88% | -43,651.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.45M | -7.39M | -13.15M | -8.02M | -9.02M | -12.37M | -6.35M | -952.14K | -38.05K | -500.00 |
| Operating Income Ratio | -1,211.74% | -3,777.44% | -43,818.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.39M | -851.99K | -346.78K | -2.26M | -251.10K | -2.17M | -825.00K | -134.48K | 0.00 | 0.00 |
| Income Before Tax | -2.05M | -8.24M | -13.49M | -10.28M | -9.27M | -14.54M | -7.17M | -1.09M | -38.05K | -500.00 |
| Income Before Tax Ratio | -721.67% | -4,213.02% | -44,973.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 506.92K | 296.22K | 1.46M | 251.10K | 760.18K | -5.87M | -937.63K | 0.00 | 0.00 |
| Net Income | -2.05M | -8.75M | -13.79M | -11.74M | -9.27M | -14.54M | -7.17M | -1.09M | -38.05K | -500.00 |
| Net Income Ratio | -721.67% | -4,472.19% | -45,961.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.08 | -0.33 | -0.62 | -0.78 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | 0.00 |
| EPS Diluted | -0.08 | -0.33 | -0.62 | -0.78 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 44.76M | 26.78M | 22.16M | 15.04M | 13.74M | 10.47M | 8.86M | 9.07M | 6.51M | 2.78M |
| Weighted Avg Shares Out (Dil) | 44.76M | 26.78M | 22.16M | 15.04M | 13.74M | 10.47M | 8.86M | 9.07M | 6.51M | 2.78M |
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, adding to the already issued patents in Korea, Canada and Japan, which the company says shows tremendous value in the liver...
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. The company already holds patents in Korea, Canada and Japan, and Uttroside B previously received...
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
Q BioMed Inc has given itself a big shot in the arm, adding a multi-million dollar asset in the form of an equity stake in long term partner Mannin Research, which has a drug development pipeline poised to be a...
Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment
Q BioMed Inc. (OTCQB:QBIO) said it has received a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) licensed from the Washington University in...
Q BioMed reports Strontium89 sales revenue surge in shareholder update
Q BioMed Inc said it has seen an uptick in sales revenue from Strontium89, the company's potential chemotherapeutic drug, in its recently reported quarter. The company's second-quarter sales revenue was nearly double its first-quarter figure, representing the company's best sales number to...
Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib
Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior safety and efficacy compared to the current FDA approved drug Sorafenib. The publication in May this...
Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets
Q BioMed Inc told investors that it had studiously avoided biotech single-asset risks by acquiring multiple assets over time, across a broad spectrum of indications in large markets and its strategy was paying dividends. The New York-based company has a...
Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer
Q BioMed Inc. (OTCQB:QBIO) has announced a new publication in the Frontiers of Oncology journal supporting the efficacy and further development of its Uttroside-B (Utt-B) chemotherapeutic to treat liver cancer. In the initial Scientific Reports study, Q BioMed said researchers...
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current pipeline of products and platforms. “From inception our goal has been to identify assets and...
Q BioMed says it is seeing a ‘significant uptrend' in revenues as it continues to roll out Strontium89
Q BioMed Inc. (OTCQB:QBIO) told shareholders that the company was seeing a significant uptrend in revenues, advancing its pipeline of assets, and was looking at an imminent up listing to the tech-dominated Nasdaq. The New York-based commercial-stage biotech company has...
Source: https://incomestatements.info
Category: Stock Reports